Nasus Pharma is trading 5.01% down now at $3.41, with no confirmed company-specific catalyst identified for the decline.
- No new company-specific announcement explaining the September 16, 2026 decline was identified.
- The latest major news was September 14 FDA clearance to begin the NS002 anaphylaxis clinical study, with pivotal testing planned for the fourth quarter of 2026.
- Broader conditions were mixed: Treasury yields and rate concerns pressured risk-sensitive shares, while major indexes showed limited movement.